Form 4: Aquestive Therapeutics SVP Lori Braender Reports Tax-Related Stock Disposal

Lori Braender, SVP and General Counsel of Aquestive Therapeutics, reports the disposal of shares to cover tax obligations related to vesting Restricted Stock Units.

Summary

• On March 9, 2024, Lori Braender, SVP and General Counsel of Aquestive Therapeutics, disposed of 10,530 shares of common stock to satisfy tax withholding obligations.
• The shares were withheld by the issuer at a price of $4.88 per share in connection with the vesting of previously granted Restricted Stock Units (RSUs).
• Following the transaction, Braender directly owns 313,231 shares of Aquestive Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock transactions for tax purposes, indicating a neutral sentiment.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency regarding insider transactions.
• Similar filings are made by executives at companies like Teva Pharmaceutical Industries Ltd. and Viatris Inc. when they have transactions involving their company's stock.
• The level of detail required in Form 4 filings is consistent across all companies subject to SEC regulations.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine disposal of shares for tax purposes.

Key Dates